Register for PhD Students - CombiGene - Internship Project VT24

CombiGene

Target Group: PhD Student (1month)

Evaluation of new Gene Therapy projects

CombiGene is an international recognized gene therapy company with solid experience and know-how. Gene therapy has seen rapid development in recent years, with several approved therapies and major corporate deals. During this period has CombiGene built up a strong position with respect to knowledge within this field in the Nordic region. We have the expertise to bring a gene therapy asset through the preclinical phase, and we know how to interact with Big Pharma.

 
CombiGene’s business concept is to develop effective gene therapies for severe life-altering 
diseases where adequate treatment is currently lacking. Our licensing and partnering efforts focus on innovative approaches, primarily on AAV-based projects where we have profound knowledge in key areas. At the same time, we do not close any doors to interesting opportunities in other areas of technology. Our primary therapeutic focus lies within diseases related to the central nervous system and metabolic diseases, where we have established solid knowledge and experience. 
Our main focus is to do what we can to improve the lives of people! 

In our portfolio we have one pain program in a joint collaboration with a Danish company with the goal to develop an effective treatment for severe chronic nerve pain. The program consists of two projects – a peptide treatment and a gene therapy treatment (AAV). We also have an epilepsy project with an AAV-based gene therapy in preclinical development targeting drug-resistant focal epilepsy. 
The company is now eager to find more gene therapy projects to expand the portfolio. 

Project Description 
The work of the student will be to aid in the evaluation of the current assets under review. 
Depending on profile and interest of candidate as well as what current project is under evaluation 
the work may include deep diving into disease and mechanism of action of target, designing viral 
vectors for candidate drug evaluation, evaluation of current pre-clinical data, competitor analysis, 
evaluation of medical need etc. The student would be one part of a great team performing the 
evaluation. 

Candidate’s Profile 
We seek for a curious person, with a good eye for evaluating science. Expertise in gene therapy is 
good but no must. He/she should be analytical and reflective, knowledge in literature review and 
report writing is a must as well as good communication skills and fluent in spoken and written 
English. 

Supervisor
The supervisor for this project has long and broad experience from the life science industry in the 
majority of different functions (clinical development, CMC, regulatory affairs, corporate business 
level), both from a corporate perspective and project leadership in all stages of drug development. 
She will provide guidance and be a discussion partner throughout the project. 

Practical details
Starting date: HT 2024. Preferable in September-October 2024 (can be discussed)
Duration: One month fulltime work or two months part-time work 
Location of work: Flexible, options are CombiGene’s office at Agavägen 52, Lidingö, & working 
‘from home’ 

Contact details: 
Birgitta Ståhl, Senior Director In-licensing 
birgitta.stahl@combigene.com 
070-380 9940

https://combigene.com/